To date, tissue expression of PD-L1 is tested by immunohistochemistry (IHC) and evaluated by microscopic assessment in all non-operable NSCLC, where the rate of expression in neoplastic cells can predict treatment response and its efficacy, indicating the place of pembrolizumab in the therapeutic algorithm (73, 74). This evidence concerns the gene CD274 and non-small cell lung carcinoma.